Cargando…

The RUDY study platform – a novel approach to patient driven research in rare musculoskeletal diseases

BACKGROUND: Research into rare diseases is becoming more common, with recognition of the significant diagnostic and therapeutic care gaps. Registries are considered a key research methodology to address rare diseases. This report describes the structure of the Rare UK Diseases Study (RUDY) platform...

Descripción completa

Detalles Bibliográficos
Autores principales: Javaid, M. K., Forestier-Zhang, L., Watts, L., Turner, A., Ponte, C., Teare, H., Gray, D., Gray, N., Popert, R., Hogg, J., Barrett, J., Pinedo-Villanueva, R., Cooper, C., Eastell, R., Bishop, N., Luqmani, R., Wordsworth, P., Kaye, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5101709/
https://www.ncbi.nlm.nih.gov/pubmed/27825362
http://dx.doi.org/10.1186/s13023-016-0528-6
_version_ 1782466332903604224
author Javaid, M. K.
Forestier-Zhang, L.
Watts, L.
Turner, A.
Ponte, C.
Teare, H.
Gray, D.
Gray, N.
Popert, R.
Hogg, J.
Barrett, J.
Pinedo-Villanueva, R.
Cooper, C.
Eastell, R.
Bishop, N.
Luqmani, R.
Wordsworth, P.
Kaye, J.
author_facet Javaid, M. K.
Forestier-Zhang, L.
Watts, L.
Turner, A.
Ponte, C.
Teare, H.
Gray, D.
Gray, N.
Popert, R.
Hogg, J.
Barrett, J.
Pinedo-Villanueva, R.
Cooper, C.
Eastell, R.
Bishop, N.
Luqmani, R.
Wordsworth, P.
Kaye, J.
author_sort Javaid, M. K.
collection PubMed
description BACKGROUND: Research into rare diseases is becoming more common, with recognition of the significant diagnostic and therapeutic care gaps. Registries are considered a key research methodology to address rare diseases. This report describes the structure of the Rare UK Diseases Study (RUDY) platform that aims to improve research processes and address many of the challenges of carrying out rare musculoskeletal disease research. RUDY is an internet-based platform with online registration, initial verbal consent, online capture of patient reported outcome measures and events within a dynamic consent framework. The database structure, security and governance framework are described. RESULTS: There have been 380 participants recruited into RUDY with completed questionnaire rates in excess of 50 %. There has been one withdrawal and two participants have amended their consent options. CONCLUSIONS: The strengths of RUDY include low burden for the clinical team, low research administration costs with high participant recruitment and ease of data collection and access. This platform has the potential to be used as the model for other rare diseases globally.
format Online
Article
Text
id pubmed-5101709
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51017092016-11-10 The RUDY study platform – a novel approach to patient driven research in rare musculoskeletal diseases Javaid, M. K. Forestier-Zhang, L. Watts, L. Turner, A. Ponte, C. Teare, H. Gray, D. Gray, N. Popert, R. Hogg, J. Barrett, J. Pinedo-Villanueva, R. Cooper, C. Eastell, R. Bishop, N. Luqmani, R. Wordsworth, P. Kaye, J. Orphanet J Rare Dis Research BACKGROUND: Research into rare diseases is becoming more common, with recognition of the significant diagnostic and therapeutic care gaps. Registries are considered a key research methodology to address rare diseases. This report describes the structure of the Rare UK Diseases Study (RUDY) platform that aims to improve research processes and address many of the challenges of carrying out rare musculoskeletal disease research. RUDY is an internet-based platform with online registration, initial verbal consent, online capture of patient reported outcome measures and events within a dynamic consent framework. The database structure, security and governance framework are described. RESULTS: There have been 380 participants recruited into RUDY with completed questionnaire rates in excess of 50 %. There has been one withdrawal and two participants have amended their consent options. CONCLUSIONS: The strengths of RUDY include low burden for the clinical team, low research administration costs with high participant recruitment and ease of data collection and access. This platform has the potential to be used as the model for other rare diseases globally. BioMed Central 2016-11-08 /pmc/articles/PMC5101709/ /pubmed/27825362 http://dx.doi.org/10.1186/s13023-016-0528-6 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Javaid, M. K.
Forestier-Zhang, L.
Watts, L.
Turner, A.
Ponte, C.
Teare, H.
Gray, D.
Gray, N.
Popert, R.
Hogg, J.
Barrett, J.
Pinedo-Villanueva, R.
Cooper, C.
Eastell, R.
Bishop, N.
Luqmani, R.
Wordsworth, P.
Kaye, J.
The RUDY study platform – a novel approach to patient driven research in rare musculoskeletal diseases
title The RUDY study platform – a novel approach to patient driven research in rare musculoskeletal diseases
title_full The RUDY study platform – a novel approach to patient driven research in rare musculoskeletal diseases
title_fullStr The RUDY study platform – a novel approach to patient driven research in rare musculoskeletal diseases
title_full_unstemmed The RUDY study platform – a novel approach to patient driven research in rare musculoskeletal diseases
title_short The RUDY study platform – a novel approach to patient driven research in rare musculoskeletal diseases
title_sort rudy study platform – a novel approach to patient driven research in rare musculoskeletal diseases
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5101709/
https://www.ncbi.nlm.nih.gov/pubmed/27825362
http://dx.doi.org/10.1186/s13023-016-0528-6
work_keys_str_mv AT javaidmk therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT forestierzhangl therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT wattsl therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT turnera therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT pontec therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT teareh therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT grayd therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT grayn therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT popertr therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT hoggj therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT barrettj therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT pinedovillanuevar therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT cooperc therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT eastellr therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT bishopn therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT luqmanir therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT wordsworthp therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT kayej therudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT javaidmk rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT forestierzhangl rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT wattsl rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT turnera rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT pontec rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT teareh rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT grayd rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT grayn rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT popertr rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT hoggj rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT barrettj rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT pinedovillanuevar rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT cooperc rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT eastellr rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT bishopn rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT luqmanir rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT wordsworthp rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases
AT kayej rudystudyplatformanovelapproachtopatientdrivenresearchinraremusculoskeletaldiseases